- Home
- GBIO vs RGC Comparison
GBIO vs RGC Comparison
Compare GBIO & RGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GBIO
- RGC
- Stock Information
- Founded
- GBIO 2016
- RGC 2014
- Country
- GBIO United States
- RGC Hong Kong
- Employees
- GBIO N/A
- RGC N/A
- Industry
- GBIO Biotechnology: Pharmaceutical Preparations
- RGC Medicinal Chemicals and Botanical Products
- Sector
- GBIO Health Care
- RGC Health Care
- Exchange
- GBIO Nasdaq
- RGC Nasdaq
- Market Cap
- GBIO 145.5M
- RGC 171.1M
- IPO Year
- GBIO 2020
- RGC 2021
- Fundamental
- Price
- GBIO $2.50
- RGC $5.32
- Analyst Decision
- GBIO Buy
- RGC
- Analyst Count
- GBIO 4
- RGC 0
- Target Price
- GBIO $7.50
- RGC N/A
- AVG Volume (30 Days)
- GBIO 63.3K
- RGC 37.2K
- Earning Date
- GBIO 08-07-2024
- RGC 10-25-2024
- Dividend Yield
- GBIO N/A
- RGC N/A
- EPS Growth
- GBIO N/A
- RGC N/A
- EPS
- GBIO N/A
- RGC N/A
- Revenue
- GBIO $13,174,000.00
- RGC N/A
- Revenue This Year
- GBIO $99.36
- RGC N/A
- Revenue Next Year
- GBIO N/A
- RGC N/A
- P/E Ratio
- GBIO N/A
- RGC N/A
- Revenue Growth
- GBIO 1397.05
- RGC N/A
- 52 Week Low
- GBIO $0.86
- RGC $3.03
- 52 Week High
- GBIO $4.65
- RGC $32.44
- Technical
- Relative Strength Index (RSI)
- GBIO 49.32
- RGC 38.69
- Support Level
- GBIO $2.13
- RGC $5.52
- Resistance Level
- GBIO $2.49
- RGC $6.57
- Average True Range (ATR)
- GBIO 0.21
- RGC 0.76
- MACD
- GBIO 0.01
- RGC -0.27
- Stochastic Oscillator
- GBIO 46.91
- RGC 0.00
About GBIO Generation Bio Co.
Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.
About RGC Regencell Bioscience Holdings Limited
Regencell Bioscience Holdings Ltd is engaged in the research, development and commercialization of traditional Chinese medicine. The medicines are used for the treatment of neurocognitive disorders and degeneration.